Aurora Cannabis Reports Record UK Revenue
Canadian cannabis producer Aurora has reported record revenues from its UK medical cannabis operations, driven by increased prescribing volumes and the expansion of its licensed product range.
Aurora Cannabis, one of Canada largest licensed cannabis producers and a significant supplier to the UK medical market, has reported record quarterly revenues from its UK operations. The company attributed the performance to substantial growth in CBMP prescription volumes and the successful addition of two new formulations to its UK licensed product portfolio.
Financial Highlights
Aurora UK-specific revenue grew by 47% year-on-year in the reported quarter, making the UK its fastest-growing international market by percentage growth. The company noted that the UK now accounts for approximately 18% of its total medical cannabis revenues globally, up from 11% in the same period the previous year.
Market Drivers
- Growing number of licensed prescribers and specialist clinics in the UK
- Increased awareness among GPs of referral pathways to specialist services
- Expansion of Aurora UK pharmacy distribution partnerships
- Launch of a new oral spray formulation that has gained rapid prescriber adoption
Investment in UK Infrastructure
Aurora confirmed that it is in advanced discussions with a UK-based pharmaceutical manufacturer regarding contract packaging and potentially local processing of some product lines. The move would reduce import dependency and potentially improve supply chain resilience for UK patients.
"The UK market continues to mature rapidly. We see it as one of the most strategically important markets globally for the next five years."
Aurora strong UK performance comes against a backdrop of wider financial restructuring at the group level, underscoring the growing strategic importance the company places on its international medical cannabis divisions.
